glycyl-arginyl-glycyl-aspartyl-seryl-proline has been researched along with Experimental Hepatoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Imlau, U; Oppermann, E; Qian, J; Qian, K; Tran, A; Vogl, TJ | 1 |
| Deng, XB; Feng, GS; Liang, HM; Ni, L; Qian, J; Wang, W; Wang, Y; Xia, F; Yin, J | 1 |
2 other study(ies) available for glycyl-arginyl-glycyl-aspartyl-seryl-proline and Experimental Hepatoma
| Article | Year |
|---|---|
Transarterial administration of integrin inhibitor loaded nanoparticles combined with transarterial chemoembolization for treating hepatocellular carcinoma in a rat model.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Proliferation; Chemoembolization, Therapeutic; Ethiodized Oil; Hepatic Artery; Immunohistochemistry; Injections, Intra-Arterial; Integrins; Liver Neoplasms, Experimental; Magnetic Resonance Imaging; Male; Matrix Metalloproteinase 9; Nanomedicine; Nanoparticles; Oligopeptides; Rats, Inbred ACI; Tumor Burden; Vascular Endothelial Growth Factor A | 2016 |
[Transarterial administration of GRGDSP combined with chemoembolization for treating hepatic carcinoma in rats].
Topics: Animals; Antineoplastic Agents; Chemoembolization, Therapeutic; Female; Hepatic Artery; Liver Neoplasms, Experimental; Oligopeptides; Rats; Rats, Wistar | 2006 |